Futibatinib, Tecentriq 1 200 mg concentrate for solution for infusion, JNJ-61186372
VHIO17002
Phase 2 small_molecule active
Quick answer
Futibatinib, Tecentriq 1 200 mg concentrate for solution for infusion, JNJ-61186372 for Subjects with advanced solid tumour is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Subjects with advanced solid tumour
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active